FindTrial
Sign In

EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE - ND

EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-003717-41-IT
Enrollment
Unknown
Registered
2007-07-12
Start date
2006-07-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MOOD DEPRESSION MedDRA version: 6.1 Level: PT Classification code 10012374

Interventions

Pharmaceutical Form: Capsule, hard Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the pla

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients attending the clinical centre for Parkinson disease of Neuroscience Department of A. Gemelli Hospital, Catholic University of Sacred Heart, in Rome with: - diagnosis of Parkinson disease - antiparkinson therapy steady since at least 6 months Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: monogenic type of Parkinson disease (diagnosis genetically confirmed) - liver insufficiency - kidney insufficiency - important coagulation failure and anticoagulant therapy - valproate therapy - presence of psychiatric disorders (psychotic disorders) severely interfering with the evaluation - pregnancy

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the tolerability and efficacy of polyunsatured fatty acids omega-3 consumption on mood (depression and anhedonia) and motor symptoms of patients suffering from Parkinson disease with steady therapy since 6 months.;Secondary Objective: ND;Primary end point(s): ND—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026